ISRCTN19844007 https://doi.org/10.1186/ISRCTN19844007

Use of erythropoietin for anaemia management, clearance of low and middle molecular weight uraemic toxins, quality of life and cost effectiveness of mid-dilution on-line haemodiafiltration compared to conventional low flux haemodialysis

Submission date
29/09/2006

Registration date
29/09/2006

Last Edited
17/05/2017

Recruitment status
No longer recruiting

Overall study status
Completed

Condition category
Haematological Disorders

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[ ] Results
[ ] Individual participant data
[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr A Chesser

Contact details
Consultant Nephrologist
Renal Office
Royal London Hospital
Whitechapel
London
United Kingdom
E1 1BB
+44 (0)20 7377 7366
alistair.chesser@bartsandthelondon.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0205168926

Study information

Scientific Title
Use of erythropoietin for anaemia management, clearance of low and middle molecular weight uraemic toxins, quality of life and cost effectiveness of mid-dilution on-line haemodiafiltration compared to conventional low flux haemodialysis

Study objectives
To quantify the effect of on-line mid-dilution haemodiafiltration on the use of erythropoietin for anaemia management in patients with end-stage renal disease compared to the technique of conventional haemodialysis.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied
Anaemia

Interventions

Not provided at time of registration

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Erythropoietin

Primary outcome measure
Control of haemoglobin and use of erythropoietin

Secondary outcome measures
Not provided at time of registration

Overall study start date
27/07/2005

Completion date
31/07/2007

Eligibility

Key inclusion criteria
Not provided at time of registration

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
80

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
27/07/2005

Date of final enrolment
31/07/2007

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
Royal London Hospital
London
United Kingdom
E1 1BB

Sponsor information

Organisation
Record Provided by the NHSTCT Register - 2006 Update - Department of Health (UK)

Sponsor details
The Department of Health, Richmond House, 79 Whitehall
London
United Kingdom
SW1A 2NL
+44 (0)20 7307 2622
dhmail@doh.gsi.org.uk

Sponsor type
Government

Website
http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type
Government

Funder Name
Barts and The London NHS Trust (UK)

Funder Name
NHS R&D Support Funding (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration